NDATOPICALCREAM
Approved
Jan 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
HALOG-E (halcinonide) by PharmaIN is corticosteroid hormone receptor agonists [moa]. First approved in 1980.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALOG-E (halcinonide) is a potent topical corticosteroid cream approved in 1980 for inflammatory and pruritic dermatological conditions. It works by agonizing corticosteroid hormone receptors to reduce inflammation and itching on affected skin. This small-molecule topical agent is indicated for conditions such as eczema, psoriasis, and other inflammatory skin disorders.
LOE Approaching
With LOE approaching and modest competitive pressure (30), brand teams are likely in defensive/transition mode with limited headcount growth.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HALOG-E offers limited career dynamism given its LOE-approaching lifecycle and zero linked job postings, suggesting small or transitioning team structures. Professionals joining this brand should expect focus on defensive strategies, margin protection, and managed decline rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on HALOG-E at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.